Shkreli Arrested On Securities Fraud; KaloBios Hit Hard
This article was originally published in Scrip
Executive Summary
When FBI agents arrested Turing Pharmaceuticals AG's CEO Martin Shkreli, who also recently was named chief of KaloBios Pharmaceuticals Inc., some had predicted it was a likely outcome after he spiked the price for a toxoplasmosis medicine, Daraprim (pyrimethamine), by more than 5,000% – catching the attention of antitrust investigators in New York and lawmakers on Capitol Hill.